| Jul 1 |
Sanofi eyes German insulin investment of up to $1.6 billion, source says
|
| Jun 29 |
Where Will Novavax Be in 1 Year?
|
| Jun 28 |
PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar
|
| Jun 28 |
3 Top Euronext Paris Dividend Stocks With Yields From 4% To 5.1%
|
| Jun 27 |
Vigil Neuroscience jumps 34% as Sanofi invests $40M
|
| Jun 27 |
Formation Bio secures $372m funds for AI-driven drug platform
|
| Jun 27 |
Sanofi reports positive data from Phase III EoE treatment trial
|
| Jun 26 |
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
|
| Jun 26 |
Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
|
| Jun 26 |
Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC
|
